Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Idexx Laboratories (IDXX) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDiagnostics & ResearchIDXX

Closing price · Nov 19, 2026 $690.95 -1.1% on the day · -0.9% over 12 months 52-week range $504.70 – $766.68
Get IDXX alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling9last 12 months
Reported sales$58.4M0 of 57 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 1, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Sharon E. Underberg, Evp, Gc & Corporate Secretary sold 6,348 shares at $688.25 ($4.4M).

Trade date
Nov 4, 2026
Disclosed to the SEC
Nov 5, 2026
Type
Sale (code S)

Read the original SEC filing ↗All IDXX insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

IDXX insider transactions (Form 4)

Open-market purchases and sales. 93 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 5SEC Sharon E. UnderbergEvp, Gc & Corporate Secretary Sell 6,3489,727 held (−39%) $688.25 $4.4M +0.4% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 4,54096,716 held (−4%) $701.36 $3.2M -1.5% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 4,075102,923 held (−4%) $699.33 $2.8M -1.2% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 3,95090,630 held (−4%) $703.45 $2.8M -1.8% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 2,13694,580 held (−2%) $702.21 $1.5M -1.6% —
Nov 5SEC Michael LanePresident Sell 2,0595,753 held (−26%) $689.70 $1.4M +0.2% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 1,945106,998 held (−2%) $698.26 $1.4M -1.0% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 1,84087,710 held (−2%) $707.84 $1.3M -2.4% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 1,667101,256 held (−2%) $700.33 $1.2M -1.3% —
Nov 5SEC Michael LanePresident Sell 1,6774,076 held (−29%) $687.46 $1.2M +0.5% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 1,50184,909 held (−2%) $710.12 $1.1M -2.7% —
Nov 5SEC Sharon E. UnderbergEvp, Gc & Corporate Secretary Sell 1,5038,224 held (−15%) $689.05 $1.0M +0.3% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 1,30086,410 held (−1%) $709.00 $922K -2.5% —
Nov 5SEC Sharon E. UnderbergEvp, Gc & Corporate Secretary Sell 1,0557,169 held (−13%) $690.02 $728K +0.1% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 84089,550 held (−1%) $707.00 $594K -2.3% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 77584,134 held (−1%) $711.31 $551K -2.9% —
Nov 5SEC Daniel M. JuniusDirector Sell 7002,861 held (−20%) $705.78 $494K -2.1% —
Nov 5SEC Daniel M. JuniusDirector Sell 5002,361 held (−17%) $701.68 $351K -1.5% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 33183,803 held (−0%) $711.95 $236K -2.9% —
Nov 5SEC Jonathan Jay MazelskyChair Sell 24090,390 held (−0%) $705.59 $169K -2.1% —
Nov 5SEC Michael LanePresident Sell 2437,812 held (−3%) $687.85 $167K +0.5% —
Sep 9SEC Lawrence D. KingsleyDirector Sell 2,2039,568 held (−19%) $532.08 $1.2M +29.9% —
Mar 5SEC Nimrata HuntPresident Sell 1,75818,141 held (−9%) $634.57 $1.1M +8.9% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 3,66091,254 held (−4%) $658.92 $2.4M +4.9% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 2,85988,395 held (−3%) $659.75 $1.9M +4.7% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 2,86094,914 held (−3%) $657.84 $1.9M +5.0% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 2,58983,606 held (−3%) $663.04 $1.7M +4.2% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,669102,887 held (−2%) $652.49 $1.1M +5.9% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,48899,117 held (−1%) $655.85 $976K +5.4% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,34397,774 held (−1%) $656.85 $882K +5.2% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,281105,651 held (−1%) $650.67 $834K +6.2% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,20087,195 held (−1%) $661.10 $793K +4.5% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,171101,716 held (−1%) $653.68 $765K +5.7% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,111100,605 held (−1%) $654.63 $727K +5.5% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,095104,556 held (−1%) $651.49 $713K +6.1% —
Mar 2SEC Jonathan Jay MazelskyCEO, President Sell 1,00086,195 held (−1%) $662.16 $662K +4.3% —
Feb 27SEC Nimrata HuntPresident Sell 2,69319,899 held (−12%) $661.54 $1.8M +4.4% —
Feb 19SEC Michael G. EricksonPresident Sell 2,69413,422 held (−17%) $628.22 $1.7M +10.0% —
Feb 19SEC Michael G. EricksonPresident Sell 1,28816,116 held (−7%) $626.26 $807K +10.3% —
Feb 19SEC Sophie V. VandebroekDirector Sell 9451,167 held (−45%) $628.65 $594K +9.9% —
Feb 19SEC Michael G. EricksonPresident Sell 68912,733 held (−5%) $629.09 $433K +9.8% —
Feb 19SEC Sophie V. VandebroekDirector Sell 519648 held (−44%) $628.56 $326K +9.9% —
Feb 19SEC Michael G. EricksonPresident Sell 45617,608 held (−3%) $623.76 $284K +10.8% —
Feb 19SEC Michael G. EricksonPresident Sell 20417,404 held (−1%) $625.24 $128K +10.5% —
Feb 19SEC Michael G. EricksonPresident Sell 4012,693 held (−0%) $629.86 $25K +9.7% —
Feb 11SEC George FennellPresident Sell 2,8099,863 held (−22%) $649.26 $1.8M +6.4% —
Feb 11SEC George FennellPresident Sell 2,78214,698 held (−16%) $646.23 $1.8M +6.9% —
Feb 11SEC George FennellPresident Sell 2,16117,480 held (−11%) $645.25 $1.4M +7.1% —
Feb 11SEC George FennellPresident Sell 1,13020,038 held (−5%) $643.00 $727K +7.5% —
Feb 11SEC George FennellPresident Sell 1,06013,638 held (−7%) $647.21 $686K +6.8% —
Feb 11SEC George FennellPresident Sell 96612,672 held (−7%) $648.78 $627K +6.5% —
Feb 11SEC George FennellPresident Sell 39719,641 held (−2%) $644.02 $256K +7.3% —
Feb 11SEC George FennellPresident Sell 409,823 held (−0%) $650.32 $26K +6.2% —
Nov 10SEC Nimrata HuntPresident Sell 5,11425,460 held (−17%) $702.20 $3.6M -1.6% —
Nov 10SEC Nimrata HuntPresident Sell 1,46822,527 held (−6%) $704.87 $1.0M -2.0% —
Nov 10SEC Nimrata HuntPresident Sell 1,46523,995 held (−6%) $703.73 $1.0M -1.8% —
Nov 10SEC Nimrata HuntPresident Sell 1,37821,149 held (−6%) $705.54 $972K -2.1% —
Historical context

Similar past setups: not applicable. IDXX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with IDXX in the Research Lab

IDXX has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

IDXX closeInsider buyInsider sale
500600700800DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-02EEarnings release filed 2026-05-05EEarnings release filed 2026-08-04EEarnings release filed 2026-11-02Sold $1,115,577 on 2026-03-03 · Nimrata HuntSold $1,172,178 on 2026-09-04 · Lawrence D. KingsleySold $4,289,959 on 2026-02-17 · Michael G. Erickson, Sophie V. VandebroekSold $7,336,993 on 2026-02-10 · George FennellSold $17,119,612 on 2026-02-26 · Jonathan Jay Mazelsky, Nimrata HuntSold $27,395,758 on 2026-11-04 · Daniel M. Junius, Jonathan Jay Mazelsky, Michael Lane, Sharon E. Underberg
Bought, 12 months$0
Sold, 12 months$58.4M
Insiders buying0
Insiders selling9

Idexx Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $58.4M of IDXX stock on the open market; P/E 46.9 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

IDXX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $6.6M sold (4 trades)Q4 2025Q1 2026: $29.9M sold (31 trades)Q1 2026Q2 2026Q3 2026: $1.2M sold (1 trades)Q3 2026Q4 2026: $27.4M sold (21 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$27.4M21
Q3 2026—0$1.2M1
Q2 2026—0—0
Q1 2026—0$29.9M31
Q4 2025—0$6.6M4

Valuation, profit and volume

P/E (trailing)46.9Sector median 25.0
Market value$55.32BDiagnostics & Research
Profit margin25.4%Revenue growth +9.9%
Volume vs. 50-day0.6×Last 5 sessions

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Idexx Laboratories insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $58.4M. 0 of 57 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

IDXX earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 2, 2026 +0.7% None +21.9%S&P -0.2% pending
Aug 4, 2026 +0.1% None +3.0%S&P +1.6% -8.4%
May 5, 2026 -4.4% None +2.9%S&P +2.2% -2.9%
Feb 2, 2026 -5.9% None -5.7%S&P -0.4% -2.2%
Nov 3, 2025 -1.2% None +14.7%S&P -1.0% -0.6%
Aug 4, 2025 +3.2% None +19.9%S&P +1.0% -0.2%
May 1, 2025 +7.1% None +9.1%S&P +2.2% +8.8%
Feb 3, 2025 -1.5% None +10.2%S&P -0.0% -7.7%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

IDXX short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

Rising
20%40%60%2026-08-26: 30% of volume sold short2026-08-27: 31% of volume sold short2026-08-28: 44% of volume sold short2026-08-31: 40% of volume sold short2026-09-01: 40% of volume sold short2026-09-02: 25% of volume sold short2026-09-03: 20% of volume sold short2026-09-04: 34% of volume sold short2026-09-08: 29% of volume sold short2026-09-09: 38% of volume sold short2026-09-10: 31% of volume sold short2026-09-11: 24% of volume sold short2026-09-14: 20% of volume sold short2026-09-15: 25% of volume sold short2026-09-16: 37% of volume sold short2026-09-17: 32% of volume sold short2026-09-18: 35% of volume sold short2026-09-21: 26% of volume sold short2026-09-22: 51% of volume sold short2026-09-23: 51% of volume sold short2026-09-24: 39% of volume sold short2026-09-25: 41% of volume sold short2026-09-28: 54% of volume sold short2026-09-29: 71% of volume sold short2026-09-30: 45% of volume sold short2026-10-01: 50% of volume sold short2026-10-02: 59% of volume sold short2026-10-05: 63% of volume sold short2026-10-06: 46% of volume sold short2026-10-07: 40% of volume sold short2026-10-08: 44% of volume sold short2026-10-09: 42% of volume sold short2026-10-12: 44% of volume sold short2026-10-13: 68% of volume sold short2026-10-14: 52% of volume sold short2026-10-15: 55% of volume sold short2026-10-16: 58% of volume sold short2026-10-19: 55% of volume sold short2026-10-20: 49% of volume sold short2026-10-21: 50% of volume sold short2026-10-22: 48% of volume sold short2026-10-23: 53% of volume sold short2026-10-26: 68% of volume sold short2026-10-27: 66% of volume sold short2026-10-28: 62% of volume sold short2026-10-29: 56% of volume sold short2026-10-30: 83% of volume sold short2026-11-02: 57% of volume sold short2026-11-03: 49% of volume sold short2026-11-04: 41% of volume sold short2026-11-05: 50% of volume sold short2026-11-06: 53% of volume sold short2026-11-09: 47% of volume sold short2026-11-10: 52% of volume sold short2026-11-11: 50% of volume sold short2026-11-12: 46% of volume sold short2026-11-13: 51% of volume sold short2026-11-16: 59% of volume sold short2026-11-17: 50% of volume sold short2026-11-18: 51% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 51%20-day average: 55%Prior 2 months: 42%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Insiders at Idexx Laboratories

InsiderBoughtSoldLast filingPast buys beat S&PScore
Jonathan Jay MazelskyChair — $33.0M Nov 18, 2026 — —
Nimrata HuntPresident — $9.5M Mar 5, 2026 — —
George FennellPresident — $7.3M Nov 12, 2026 — —
Sharon E. UnderbergEvp, Gc & Corporate Secretary — $6.1M Nov 5, 2026 — —
Michael G. EricksonPresident — $3.4M Feb 19, 2026 — —
Michael LanePresident — $2.7M Nov 20, 2026 — —
Lawrence D. KingsleyDirector — $1.2M Sep 9, 2026 — —
Sophie V. VandebroekDirector — $920K May 11, 2026 — —
Daniel M. JuniusDirector — $845K Nov 5, 2026 — —
Joseph L. HooleyDirector — — Nov 3, 2026 — —
Andrew EmersonCFO — — Aug 24, 2026 — —
Karen PeacockDirector — — May 11, 2026 — —
M. Anne SzostakDirector — — May 11, 2026 — —
Michael SchreckPresident — — Feb 17, 2026 — —
Martin Alexander SmithPresident — — Feb 17, 2026 — —
Michael Perkins JohnsonPresident — — Feb 17, 2026 — —

Board links: companies that share insiders with IDXX

Directors and executives who filed Form 4s for IDXX and another company in the last 12 months.

See the map →
  • APTVAptiv Joseph L. Hooley Director here · Director at APTV · latest filing Nov 3, 2026
  • DBXDropbox Karen Peacock Director here · Director at DBX · latest filing Jul 31, 2026
  • MIRMirion Technologies Lawrence D. Kingsley Director here · Director at MIR · latest filing Sep 9, 2026
  • PODDInsulet Jonathan Jay Mazelsky Chair here · Director at PODD · latest filing Nov 18, 2026
  • RVTYRevvity Sophie V. Vandebroek Director here · Director at RVTY · latest filing May 11, 2026
  • XOMExxonMobil Joseph L. Hooley Director here · Director at XOM · latest filing Nov 3, 2026
  • XRAYDENTSPLY SIRONA Jonathan Jay Mazelsky Chair here · Director at XRAY · latest filing Nov 18, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

IDXX stock: common questions

Are Idexx Laboratories insiders buying IDXX stock?

No. No Idexx Laboratories insider reported an open-market purchase of IDXX in the past 12 months.

Are Idexx Laboratories insiders selling IDXX stock?

9 insiders reported sales worth $58.4M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is IDXX's P/E ratio?

IDXX trades at about 46.9 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is IDXX's 52-week range?

Over the past year IDXX has traded between $504.70 and $766.68. It last closed at $690.95 on Nov 19, 2026.